Mechanistic targets and phytochemical strategies for breaking the obesity-cancer link

Frontiers in Oncology

Volumn 3 AUG, Issue , 2013, Pages

  Ford, Nikki A ^a   Lashinger, Laura M ^a   Allott, Emma H ^b   Hursting, Stephen D ^a,c  

^a University of Texas at Austin   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer prevention; Inflammation; Metabolism; MTOR pathway; Obesity; Phytochemicals

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CURCUMIN; CYCLOOXYGENASE 2; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; QUERCETIN; RESVERATROL; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; STAT PROTEIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; URSOLIC ACID; VASCULOTROPIN;

CALORIC RESTRICTION; CANCER GROWTH; CANCER RISK; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; INSULIN SENSITIVITY; METABOLIC SYNDROME X; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OBESITY; OXIDATIVE PHOSPHORYLATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHYTOCHEMISTRY; PREVALENCE; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84884826249     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00209     Document Type: Review

References (69)

1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA (2010) 303:235-41. doi:10.1001/jama.2009.2014
2. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race, and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report (2009) 13:1-7.
3. Hursting SD, Berger NA. Energy balance, host-related factors, and cancer progression. J Clin Oncol (2010) 28:4058-65. doi:10.1200/JCO.2010.27.9935
4. Carter JC, Church FC. Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-gamma and plasminogen activator inhibitor-1. PPAR Res (2009) 2009:345320.
5. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol (2006) 26:968-76. doi:10.1161/01.ATV.0000216787.85457.f3
6. Dunlap SM, Chiao LJ, Nogueira L, Usary J, Perou CM, Varticovski L, et al. Obesity enhances epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models. Cancer Prev Res (Phila) (2012) 5:930-42. doi:10.1158/1940-6207.CAPR-12-0034
7. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective. Washington, DC: AICR (2007).
8. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospective studied cohort of U.S. adults. N Engl J Med (2003) 348:1625-38. doi:10.1056/NEJMoa021423
9. Braun S, Bitton-Worms K, LeRoith D. The link between the metabolic syndrome and cancer. Int J Biol Sci (2011) 7:1003-15. doi:10.7150/ijbs.7.1003
10. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer (2012) 12:159-69. doi:10.1038/nrc3215
11. Hursting SD, Smith SM, Lashinger LM, Harvey AE, Perkins SN. Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research. Carcinogenesis (2010) 31:83-9. doi:10.1093/carcin/bgp280
12. Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev (2010) 20:87-90. doi:10.1016/j.gde.2009.11.002
13. Memmott RM, Dennis PA. Akt-dependent and-independent mechanisms of mTOR regulation in cancer. Cell Signal (2009) 21:656-64. doi:10.1016/j.cellsig.2009.01.004
14. Lindsley JE, Rutter J. Nutrient sensing and metabolic decisions. Comp Biochem Physiol B Biochem Mol Biol (2004) 139:543-59. doi:10.1016/j.cbpc.2004.06.014
15. Moore T, Beltran LD, Carbajal S, Strom S, Traag J, Hursting SD, et al. Dietary energy balance modulates signaling through the Akt/mammalian target of rapamycin pathway in multiple epithelial tissues. Cancer Prev Res (Phila) (2008) 1:65-76. doi:10.1158/1940-6207.CAPR-08-0022
16. De Angel RE, Conti CJ, Wheatley KE, Brenner AJ, deGraffenried LA, Hursting SD. The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by Rad001. Mol Carcinog (2012) 52:446-58. doi:10.1002/mc.21878
17. Nogueira LM, Dunlap SM, Ford NA, Hursting SD. Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity. Endocr Relat Cancer (2012) 19:57-68. doi:10.1530/ERC-11-0213
18. Gautron L, Elmquist JK. Sixteen years and counting: an update on leptin in energy balance. J Clin Invest (2011) 121:2087-93. doi:10.1172/JCI45888
19. Villanueva EC, Myers MG. Leptin receptor signaling and the regulation of mammalian physiology. Int J Obes (2008) 32:S8-12. doi:10.1038/ijo.2008.232
20. Vaiopoulos AG, Marinou K, Christodoulides C, Koutsilieris M. The role of adiponectin in human vascular physiology. Int J Cardiol (2012) 155:188-93. doi:10.1016/j.ijcard.2011.07.047
21. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr (2007) 86:s858-66.
22. Stofkova A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul (2009) 43:157-68.
23. Stattin P, Lukanova A, Biessy C, Soderberg S, Palmqvist R, Kaaks R, et al. Obesity and colon cancer: does leptin provide a link? Int J Cancer (2004) 109:149-52. doi:10.1002/ijc.11668
24. Chang S, Hursting SD, Contois JH, Strom SS, Yamamura Y, Babaian RJ, et al. Leptin and prostate cancer. Prostate (2001) 46:62-7. doi:10.1002/1097-0045(200101)46:1<62::AID-PROS1009>3.0.CO;2-V
25. Wu MH, Chou YC, Chou WY, Hsu GC, Chu CH, Yu CP, et al. Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer (2009) 100:578-82. doi:10.1038/sj.bjc.6604913
26. Fenton JI, Hord NG, Lavigne JA, Perkins SN, Hursting SD. Leptin, insulin-like growth factor-1, and insulin-like growth factor-2 are mitogens in ApcMin/+ but not Apc+/+ colonic epithelial cells. Cancer Epidemiol Biomarkers Prev (2005) 14:1646-52. doi:10.1158/1055-9965.EPI-04-0916
27. Grossmann ME, Nkhata KJ, Mizuno NK, Ray A, Cleary MP. Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer (2008) 98:370-9. doi:10.1038/sj.bjc.6604166
28. Rzepka-Gorska I, Bedner R, Cymbaluk-Ploska A, Chudecka-Glaz A. Serum adiponectin in relation to endometrial cancer and endometrial hyperplasia with atypia in obese women. Eur J Gynaecol Oncol (2008) 29:594-7.
29. Tian YF, Chu CH, Wh MH, Chang CL, Yang T, Chou YC, et al. Anthropometric measures, plasma adiponectin, and breast cancer risk. Endocr Relat Cancer (2007) 14:669-77. doi:10.1677/ERC-06-0089
30. Wei EK, Giovannucci E, Fuch CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst (2005) 97:1688-94. doi:10.1093/jnci/dji376
31. Sher DJ, Oh WH, Jacobus S, Regan MM, Lee GS, Mantzoros C. Relationship between serum adiponectin and prostate cancer grade. Prostate (2008) 68:1592-8. doi:10.1002/pros.20823
32. Cleary MP, Ray A, Rogozina OP, Dogan S, Grossman ME. Targeting the adiponectin:leptin ratio for postmenopausal breast cancer prevention. Front Biosci (2009) 1:329-57. doi:10.2741/e30
33. Li H, Stampfer MJ, Mucci L, Rifai N, Qui W, Kurth T, et al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem (2010) 56:34-43. doi:10.1373/clinchem.2009.133272
34. Yamaji T, Iwasaki M, Sasazuki S, Tsugane S. Interaction between adiponectin and leptin influences the risk of colorectal adenoma. Cancer Res (2010) 70:5430-7. doi:10.1158/0008-5472.CAN-10-0178
35. Gupta SC, Kim JH, Kannappan R, Reuter S, Doughtery PM, Aggarwal BB. Role of nuclear factorkB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents. Exp Biol Med (2012) 236:658-71.
36. Subbaramaiah K, Howe LR, Bhardway P, Du B, Gravaghi C, Yantiss RK, et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) (2011) 4:329-46. doi:10.1158/1940-6207.CAPR-10-0381
37. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol (2010) 72:219-46. doi:10.1146/annurev-physiol-021909-135846
38. O'Rourke RW. Inflammation in obesity-related diseases. Surgery (2009) 145:255-9. doi:10.1016/j.surg.2008.08.038
39. Renehan AG, Roberts DL, Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem (2008) 114:71-83. doi:10.1080/13813450801954303
40. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature (2006) 441:431-6. doi:10.1038/nature04870
41. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet (2001) 357:539-45. doi:10.1016/S0140-6736(00)04046-0
42. Foltz CJ, Fox JG, Cahill R, Murphy JC, Yan L, Shames B, et al. Spontaneous inflammatory bowel disease in multiple mutant mouse lines: association with colonization by Helicobacter hepaticus. Helicobacter (1998) 3:69-78. doi:10.1046/j.1523-5378.1998.08006.x
43. Coussens LM, Werb Z. Inflammation and cancer. Nature (2002) 420:860-7. doi:10.1038/nature01322
44. Allavena P, Sica A, Garlanda C, Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev (2008) 222:155-61. doi:10.1111/j.1600-065X.2008.00607.x
45. Koki A, Khan NK, Woerner BM, Dannenberg AJ, Olson L, Seibert K, et al. Cyclooxygenase-2 in human pathological disease. Adv Exp Med Biol (2002) 507:177-84. doi:10.1007/978-1-4615-0193-0_28
46. Iwaki T, Urano T, Umemura K. PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol (2012) 157:291-8. doi:10.1111/j.1365-2141.2012.09074.x
47. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med (2005) 9:777-94. doi:10.1111/j.1582-4934.2005.tb00379.x
48. Liu Y, Tamimi RM, Collins LC, Schnitt SJ, Gilmore HL, Connolly JL, et al. The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study. Breast Cancer Res Treat (2011) 129:175-84. doi:10.1007/s10549-011-1432-3
49. Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest (2007) 117:2362-8. doi:10.1172/JCI32239
50. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res (2004) 5A:2783-840.
51. Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res (2012) 32:537-41. doi:10.1016/j.nutres.2012.06.003
52. Ghanim H, Sia CL, Abuaysheh S, Korzeniewski K, Patnaik P, Marumganti A, et al. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab (2010) 95:E1-8. doi:10.1210/jc.2010-0482
53. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol (2006) 71:1397-421. doi:10.1016/j.bcp.2006.02.009
54. Morselli E, Maiuri MC, Markaki M, Megalou E, Pasparaki A, Palikaras K, et al. The life span-prolonging effect of sirtuin-1 is mediated by autophagy. Autophagy (2010) 6:186-8. doi:10.4161/auto.6.1.10817
55. Lanzilli G, Fuggetta MP, Tricarico M, Cottarelli A, Serafino A, Falchetti R, et al. Resveratrol down-regulates the growth and telomerase activity of breast cancer cells in vitro. Int J Oncol (2006) 28:641-8.
56. Liu W, Tan X, Shu L, Sun H, Song J, Jin P, et al. Ursolic acid inhibits cigarette smoke extract-induced human bronchial epithelial cell injury and prevents development of lung cancer. Molecules (2012) 17:9104-15. doi:10.3390/molecules17089104
57. Li J, Liang X, Yang X. Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-?B pathways. Oncol Rep (2012) 28:501-10. doi:10.3892/or.2012.1827
58. Prasad S, Yadav VR, Sung B, Reuter S, Kannappan R, Deorukhkar A, et al. Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine. Clin Cancer Res (2012) 18:4942-53. doi:10.1158/1078-0432.CCR-11-2805
59. De Angel RE, Smith SM, Glickman RD, Perkins SN, Hursting SD. Antitumor effects of ursolic acid in a mouse model of postmenopausal breast cancer. Nutr Cancer (2010) 62:1074-86. doi:10.1080/01635581.2010.492092
60. Kanjoormana M, Kuttan G. Antiangiogenic activity of ursolic acid. Integr Cancer Ther (2010) 9:224-35. doi:10.1177/1534735410367647
61. Epstein J, Sanderson IR, Macdonald TT. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr (2010) 103:1545-57. doi:10.1017/S0007114509993667
62. Zhou H, Luo Y, Huang S. Updates of mTOR inhibitors. Anticancer Agents Med Chem (2010) 10:571-81. doi:10.2174/187152010793498663
63. Binion DG, Otterson MF, Rafiee P. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut (2008) 57:1509-17. doi:10.1136/gut.2008.152496
64. Shehzad A, Khan S, Sup Lee Y. Curcumin molecular targets in obesity and obesity-related cancers. Future Oncol (2012) 8:179-90. doi:10.2217/fon.11.145
65. Aggarwal BB. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr (2010) 30:173-99. doi:10.1146/annurev.nutr.012809.104755
66. Zhang X, Chen L-X, Ouyang L, Cheng Y, Liu B. Plant natural compounds: targeting pathways of autophagy as anti-cancer therapeutic agents. Cell Prolif (2012) 45:466-76. doi:10.1111/j.1365-2184.2012.00833.x
67. Vargas AJ, Burd R. Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management. Nutr Rev (2010) 68:418-28. doi:10.1111/j.1753-4887.2010.00301.x
68. Pratheeshkumar P, Budhraja A, Son YO, Wang X, Zhang Z, Ding S, et al. Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS ONE (2012) 7:e47516. doi:10.1371/journal.pone.0047516
69. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res (1996) 4:659-68.